Development of a Novel Malarial Vaccine Design: A Hypothetical Approach

Author(s): C. Subathra Devi, Priyanka Verma, Saumya Srivastava, Pranali Ravikumar, Vishal Kalwani, Aishwarya Tandon, V. Mohanasrinivasan

Journal Name: Current Drug Discovery Technologies

Volume 11 , Issue 4 , 2014

Become EABM
Become Reviewer


P. falciparum is highly virulent in nature because of its ability to modify the infected host red blood cells, adherence to the vascular endothelium and changes in antigenicity at different stages. Also slow migration time in the dermal and endothelial cells leads to decreased immune response. To overcome the problems, there is a need to design a vaccine which increases the migration time of the parasite, enhances the immune response, enables recognition of surface antigens and causes minimal clinical infection as a side-effect. An ITI-based (Infection-Treatment Immunization) vaccine development strategy is to be adopted to develop this novel vaccine. This will include administration of a liquid solution of purified, non-attenuated sporozoites from an infected female Anopheles mosquito, AS02A adjuvant and chlorate (a metabolic inhibitor of sulfation that decreases the extent of GAG sulfation). To control infection, a drug-cover of artemisinin will be administered as a part of the vaccination strategy along with a specific protease inhibitor MRT12113 which prevents RBC rupture and reinvasion by the parasite. This vaccine will intend to increase the overall migration time of the parasite in blood which is otherwise approximately 30 minutes, resulting in an overall enhanced immune response. It also intends to reduce parasite invasion in cells and their consequent rupture thus preventing the clinical condition-malaria.

Keywords: ITI-based vaccine, malaria, Plasmodium, vaccine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 07 May, 2015
Page: [239 - 242]
Pages: 4
DOI: 10.2174/1570163811666141106102325
Price: $65

Article Metrics

PDF: 25